文献速递类风湿关节炎

类风湿关节炎持续缓解:临床深度缓解的作用及其对减药的启示

Sustaining remission in rheumatoid arthritis: the role of clinical deep remission and its implications for drug tapering.
PubMed 文献 · RMD Open · 2026-04-24

这项真实世界队列研究纳入145例达到DAS28-CRP缓解且随访5年的RA患者,按临床深度缓解(CliDR)状态分层。5年持续缓解率CliDR组为62.5%,非CliDR组为38.1%(p=0.014);非CliDR组减药使复发风险增加8.47倍,而CliDR组减药对复发风险的影响显著减弱(交互HR=0.26,p=0.046)。

要点

  • 达到临床深度缓解的RA患者5年持续缓解率显著更高。
  • 未达临床深度缓解者减药与复发风险显著升高相关。
  • 临床深度缓解可减弱减药对复发风险的不利影响。

核心结论

  • 达到临床深度缓解与RA持续缓解率显著更高相关,减药安全性取决于是否先达到临床深度缓解。

研究设计与样本

  • 真实世界队列研究,541例入组,纳入145例达到DAS28-CRP缓解且缓解后随访5年的RA患者,按临床深度缓解状态分层。

主要发现

  • 5年持续缓解率CliDR组为62.5%(95%CI 45.3%至77.1%),非CliDR组为38.1%(95%CI 29.6%至47.3%),差异有统计学意义(p=0.014)。
  • 非CliDR组中减药与复发风险增加8.47倍相关(HR=8.47,95%CI 5.01至14.32,p<0.001)。
  • 分组与减药的交互作用有统计学意义(HR=0.26,95%CI 0.07至0.98,p=0.046),CliDR组减药对复发风险的影响较非CliDR组显著减弱。

关键数值与推荐

  • 临床深度缓解定义为无压痛/肿胀关节且CRP/红细胞沉降率正常。
  • 持续缓解率随时间下降,但CliDR组各时点均高于非CliDR组。

临床怎么用

  • 对达到临床深度缓解的RA患者,减药对复发风险的影响较小,可考虑作为减药决策的参考依据。
  • 未达到临床深度缓解者减药复发风险显著升高,减药需谨慎评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: While sustained remission is the treatment goal for rheumatoid arthritis (RA), its long-term remission remains challenging. This real-world study aimed to assess the role of clinical deep remission (CliDR) in sustained remission and the risk of relapse, as well as its interaction with drug tapering. METHODS: Of the 541 patients enrolled in the cohort, 145 who achieved a Disease Activity Score in 28 joints using C reactive protein (CRP) remission with 5 years of follow-up after remission were included in this study. Participants were stratified by CliDR status (defined as no tender/swollen joints with normal CRP/erythrocyte sedimentation rate). Kaplan-Meier analysis was used to compare sustained remission rates. Multivariable Cox regression with time-dependent covariates was performed to identify independent predictors and to assess the interaction between CliDR and drug tapering. RESULTS: The sustained remission rate declined over time but was significantly higher in the CliDR group (62.5%; 95% CI 45.3% to 77.1%) than the non-CliDR group (38.1%; 95% CI 29.6% to 47.3%) at 5 years (p=0.014). In the non-CliDR group, tapering was associated with an 8.47-fold increase in the hazard of relapse (HR=8.47, 95% CI 5.01 to 14.32, p<0.001). The interaction between group and tapering was statistically significant (HR=0.26, 95% CI 0.07 to 0.98, p=0.046), indicating that the effect of tapering on relapse risk was significantly attenuated in the CliDR group compared with the non-CliDR group. CONCLUSIONS: Our findings suggest that achieving CliDR is associated with significantly higher sustained remission rates in RA and that the safety of treatment tapering is contingent on prior achievement of CliDR.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Li H, Zhou M, Zhu H, et al. Sustaining remission in rheumatoid arthritis: the role of clinical deep remission and its implications for drug tapering. RMD Open. 2026. PMID: 42031507. doi:10.1136/rmdopen-2025-006387

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。